Rury R Holman

Oct 9, 2024 | onlinelibrary.wiley.com | João Sérgio Neves |Ana Rita Leite |Robert J. Mentz |Rury R Holman

Supporting Information Filename Description ejhf3478-sup-0001-Supinfo.docxWord 2007 document , 699.2 KB Appendix S1. Supporting Information. References 1, , , , , , et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653–662.

Mar 29, 2024 | digitalcommons.library.tmc.edu | Rury R Holman |M Angelyn Bethel |Robert J. Mentz |Vivian P. Thompson

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly.